LDH-H
|
Melanoma
|
LDH-H
|
Melanoma
|
PD-L1 inhibitor Sensitive: B - Late Trials
|
PD-L1 inhibitor Sensitive: B - Late Trials
|
LDH-H
|
Melanoma
|
LDH-H
|
Melanoma
|
trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials
|
trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials
|
LDH-H
|
Gastric Cancer
|
LDH-H
|
Gastric Cancer
|
ramucirumab Resistant: C3 – Early Trials
|
ramucirumab Resistant: C3 – Early Trials
|
LDH-H
|
Melanoma
|
LDH-H
|
Melanoma
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
LDH-H
|
Uveal Melanoma
|
LDH-H
|
Uveal Melanoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
LDH-H
|
Uveal Melanoma
|
LDH-H
|
Uveal Melanoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
LDH-H
|
Uveal Melanoma
|
LDH-H
|
Uveal Melanoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
LDH-H
|
Triple Negative Breast Cancer
|
LDH-H
|
Triple Negative Breast Cancer
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
LDH-H
|
HER2 Positive Breast Cancer
|
LDH-H
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
|
LDH-H
|
Melanoma
|
LDH-H
|
Melanoma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
LDH-H
|
Melanoma
|
LDH-H
|
Melanoma
|
camrelizumab + rivoceranib Resistant: C3 – Early Trials
|
camrelizumab + rivoceranib Resistant: C3 – Early Trials
|
LDH-H
|
Lymphoma
|
LDH-H
|
Lymphoma
|
axicabtagene ciloleucel Resistant: C3 – Early Trials
|
axicabtagene ciloleucel Resistant: C3 – Early Trials
|